Evercore ISI Sticks to Its Sell Rating for Renaissancere Holdings (RNR)
Buy Rating Affirmed for Tenet Healthcare on Strong Financials and Growth Prospects
JPMorgan Adjusts Price Target on RenaissanceRe to $267 From $265, Maintains Neutral Rating
RenaissanceRe Price Target Raised to $267.00/Share From $265.00 by JP Morgan
RenaissanceRe Holdings Analyst Ratings
Tenet Healthcare Price Target Raised to $168.00/Share From $112.00 by Cantor Fitzgerald
Tenet Healthcare Analyst Ratings
Morgan Stanley Maintains RenaissanceRe Holdings(RNR.US) With Hold Rating, Maintains Target Price $240
Loop Capital Maintains Carlisle Companies(CSL.US) With Buy Rating, Maintains Target Price $475
Oppenheimer Maintains Carlisle Companies(CSL.US) With Buy Rating, Raises Target Price to $475
Carlisle Companies (CSL) Receives a Rating Update From a Top Analyst
Analysts Offer Insights on Industrial Goods Companies: Nordson (NDSN) and Carlisle Companies (CSL)
Truist Financial Maintains Tenet Healthcare(THC.US) With Buy Rating, Raises Target Price to $170
Truist Raises Price Target on Tenet Healthcare to $170 From $155, Keeps Buy Rating
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW) and Tenet Healthcare (THC)
Wells Fargo Maintains RenaissanceRe Holdings(RNR.US) With Buy Rating, Maintains Target Price $288
Citi Maintains Tenet Healthcare(THC.US) With Buy Rating, Raises Target Price to $171
Tenet Healthcare (THC) Receives a Buy From Citi
Buy Rating Affirmed on Renaissancere Holdings Amid Strong Q2 Earnings and Strategic Capital Management
KBW Maintains RenaissanceRe Holdings(RNR.US) With Buy Rating, Raises Target Price to $283